|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1ST TIME HERE?.....CLICK THE FLASHING RED BUTTON ON THE LEFT! | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
November 22, 2005ChemoCentryx to Initiate Clinical Studies of CCR2 Antagonist CCX915
BIO.COM:MORE: "ChemoCentryx, Inc., a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing orally-administered therapeutics that target the chemokine system, announced that the company has filed an Investigational New Drug Application (IND) with the U.S. Food and Drug Administration to begin clinical studies of a proprietary small molecule inhibitor of the CCR2 chemokine receptor with which it expects to complete Phase I studies in 2006."
|